Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 4
2011 8
2012 8
2013 4
2014 15
2015 11
2016 4
2017 13
2018 16
2019 17
2020 12
2021 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25275068

114 results

Results by year

Filters applied: . Clear all
Page 1
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.
Lakomy R, Poprach A, Bortlicek Z, Melichar B, Chloupkova R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Juracek J, Fiala O, Kopecky J, Finek J, Dusek L, Hejduk K, Buchler T. Lakomy R, et al. BMC Cancer. 2017 Dec 21;17(1):880. doi: 10.1186/s12885-017-3901-5. BMC Cancer. 2017. PMID: 29268716 Free PMC article.
Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
Numakura K, Muto Y, Naito S, Hatakeyama S, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Obara W, Ohyama C, Tsuchiya N, Habuchi T. Numakura K, et al. Cancer Med. 2021 Sep;10(17):5839-5846. doi: 10.1002/cam4.4130. Epub 2021 Jul 27. Cancer Med. 2021. PMID: 34313025 Free PMC article.
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C. Iacovelli R, et al. Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632. Anticancer Drugs. 2018. PMID: 29846246
114 results